What is Lumicks?
Lumicks is a prominent life science tools company specializing in the development of advanced equipment for Dynamic Single-Molecule and Cell Avidity analysis. These two rapidly emerging areas are critical for breakthroughs in biology research and the burgeoning field of immuno-oncology, positioning Lumicks at the forefront of scientific innovation.
How much funding has Lumicks raised?
Lumicks has raised a total of $93M across 1 funding round:
Series D
$93M
Series D (2021): $93M with participation from Irving Investors, Farallon Capital Management LLC, Pura Vida Investments LLC, and Lauxera Capital Partners
Key Investors in Lumicks
Irving Investors
Irving Investors is likely a venture capital firm focused on providing growth capital to innovative companies, potentially within the technology or life sciences sectors.
Farallon Capital Management LLC
Farallon Capital Management LLC is a global investment management firm known for its expertise in credit and equity investments, often engaging in complex and opportunistic financing.
Pura Vida Investments LLC
Pura Vida Investments LLC appears to be an investment entity that participates in funding rounds, likely seeking opportunities in high-growth sectors.
What's next for Lumicks?
The substantial enterprise-level funding Lumicks has attracted indicates a strong market validation and provides the necessary resources for scaling its operations and further research and development. This strategic investment is expected to accelerate the company's growth trajectory, enabling it to expand its product offerings and deepen its impact on critical areas of biological and medical research. Lumicks is poised to further solidify its leadership in providing essential tools for cutting-edge scientific discovery.
See full Lumicks company page
